


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:49:52Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406812" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406812</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>openheart</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Heart</journal-id><journal-id journal-id-type="iso-abbrev">Open Heart</journal-id><journal-id journal-id-type="pmc-domain-id">2513</journal-id><journal-id journal-id-type="pmc-domain">openheart</journal-id><journal-id journal-id-type="publisher-id">openhrt</journal-id><journal-title-group><journal-title>Open Heart</journal-title></journal-title-group><issn pub-type="epub">2053-3624</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406812</article-id><article-id pub-id-type="pmcid-ver">PMC12406812.1</article-id><article-id pub-id-type="pmcaid">12406812</article-id><article-id pub-id-type="pmcaiid">12406812</article-id><article-id pub-id-type="pmid">40889951</article-id><article-id pub-id-type="doi">10.1136/openhrt-2025-003268</article-id><article-id pub-id-type="publisher-id">openhrt-2025-003268</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Valvular Heart Disease</subject></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject></subj-group></article-categories><title-group><article-title>Relationship between left ventricular wall stress and cardiac remodelling post-TAVR and MitraClip</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9506-858X</contrib-id><name name-style="western"><surname>Papapostolou</surname><given-names initials="S">Stavroula</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kearns</surname><given-names initials="JS">John Shapland</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Costello</surname><given-names initials="B">Benedict</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>O&#8217;Brien</surname><given-names initials="J">Jessica</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-2294-6142</contrib-id><name name-style="western"><surname>Gutman</surname><given-names initials="S">Sarah</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nanayakkara</surname><given-names initials="S">Shane</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kaye</surname><given-names initials="DM">David M</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Walton</surname><given-names initials="A">Antony</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hare</surname><given-names initials="J">James</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stub</surname><given-names initials="D">Dion</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Taylor</surname><given-names initials="A">Andrew</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp"/></contrib><aff id="aff1"><label>1</label><institution>Alfred Health</institution>, <addr-line content-type="city">Melbourne</addr-line>, <addr-line content-type="state">Victoria</addr-line>, <country>Australia</country></aff><aff id="aff2"><label>2</label><institution>Monash University</institution>, <addr-line content-type="city">Melbourne</addr-line>, <addr-line content-type="state">Victoria</addr-line>, <country>Australia</country></aff><aff id="aff3"><label>3</label><institution>Western Health</institution>, <addr-line content-type="city">Footscray</addr-line>, <addr-line content-type="state">Victoria</addr-line>, <country>Australia</country></aff><aff id="aff4"><label>4</label><institution>Baker Heart Research Institute</institution>, <addr-line content-type="city">Melbourne</addr-line>, <addr-line content-type="state">Victoria</addr-line>, <country>Australia</country></aff></contrib-group><author-notes><corresp id="cor1">Prof Andrew Taylor; <email xlink:href="a.taylor@alfred.org.au">a.taylor@alfred.org.au</email></corresp><fn fn-type="COI-statement" id="fn4"><p>None declared.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>31</day><month>8</month><year>2025</year></pub-date><volume>12</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">492641</issue-id><elocation-id>e003268</elocation-id><history><date date-type="received"><day>27</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>30</day><month>7</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>08</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:&#160;<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="openhrt-12-2.pdf"/><self-uri xlink:title="pdf" xlink:href="openhrt-12-2.pdf"/><abstract><title>Abstract</title><sec><title>Background</title><p>The relationship between left ventricular wall stress (LVWS) and cardiac remodelling post structural intervention has not previously been examined. We examined the relationship between LVWS and cardiac remodelling 6 months post transcatheter aortic valve replacement (TAVR) and MitraClip (MC).</p></sec><sec><title>Methods</title><p>LVWS was calculated in 40 patients with severe aortic stenosis (AS) and 11 patients with severe mitral regurgitation (MR) immediately preintervention and postintervention with TAVR or MC. LVWS was calculated by integrating invasive haemodynamic data with cardiac MR (CMR)-derived measures of left ventricular (LV) volume and mass. Patients underwent a 6&#8201;min walk test (6MWT), transthoracic echocardiogram and CMR preprocedure and 6 months postprocedure.</p></sec><sec><title>Results</title><p>Both TAVR and MC resulted in significant improvements in functional capacity and cardiac remodelling with no significant difference in the degree of LV mass or volume reduction between the two groups.</p><p>Linear regression analysis showed that baseline diastolic LVWS (D-LVWS) in the MC cohort and baseline systolic LVWS (S-LVWS) in the TAVR cohort were predictors of larger LV end-diastolic volumes (EDV) and lower ejection fractions (EF) at follow-up (in the MC cohort: B=7.86, p=0.015 for EDV, B=&#8722;1.4, p=0.02 for EF; in the TAVR cohort: B=1.53, p=0.04 for EDV and B=&#8722;0.702, p&lt;0.001 for EF).</p></sec><sec><title>Conclusions</title><p>Higher baseline D-LVWS in patients undergoing MC, and higher baseline S-LVWS in patients undergoing TAVR, were predictors of poorer EF and larger LV volumes at follow-up. These findings suggest that LVWS may be used to predict the degree of LV recovery postprocedure and suggest that intervening below a certain LVWS threshold may lead to better outcomes with regards to cardiac remodelling.</p></sec><sec><title>Condensed abstract</title><p>LVWS was calculated in patients with AS and mitral regurgitation (MR) pre and immediately post valve intervention with TAVR or MC. The patients were followed up at 6 months with 6MWT, echocardiography and CMR imaging Both cohorts demonstrated significant functional improvements and cardiac remodelling postprocedure. Baseline D-LVWS in MC and baseline S-LVWS in TAVR were predictors of poorer EF and larger LV volumes at follow-up. This suggests that in patients with severe AS or MR, baseline LVWS may be useful to predict degree of recovery postintervention or determine need for early intervention.</p></sec></abstract><kwd-group><kwd>Transcatheter Aortic Valve Replacement</kwd><kwd>Mitral Valve Insufficiency</kwd><kwd>Magnetic Resonance Angiography</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>WHAT IS ALREADY KNOWN ON THIS TOPIC</title></caption><sec><title>WHAT THIS STUDY ADDS</title><list list-type="bullet" list-content="ul"><list-item><p>This study shows that high baseline D-LVWS in MR and high S-LVWS in AS are predictors of less beneficial cardiac remodelling 6 months post-MC and TAVR, respectively.</p></list-item></list></sec><sec><title>HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY</title><list list-type="bullet" list-content="ul"><list-item><p>In the future, LVWS may prove to be a useful marker to predict cardiac decompensation and/or guide timing of intervention.</p></list-item></list></sec></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p> Aortic stenosis (AS) and mitral regurgitation (MR) are two of the most common valve conditions. There have been significant advancements in the treatment of these conditions in the last decade. Minimally invasive structural interventions such as transcatheter aortic valve replacement (TAVR) and transcatheter edge-to-edge repair (TEER), such as MitraClip (MC), are increasingly being performed as an alternative to conventional open-heart surgery. Patients who may have previously been deemed too high risk for conventional surgery can now be offered the option of percutaneous intervention.</p><p>With the advent of these minimally invasive procedures and improved procedural outcomes over the years, there is increasing interest in finding markers to help guide optimal timing of intervention.</p><p>Left ventricular wall stress (LVWS) is thought to be important in the remodelling seen in valve disease. Prior studies have shown that the concentric hypertrophy that occurs in AS helps maintain both systolic (S-LVWS) and diastolic LVWS (D-LVWS) within normal levels. If the compensatory hypertrophy is inadequate, decompensation occurs with increases in S-LVWS. In MR, the chronic volume overload leads to LV dilatation and eccentric hypertrophy in an attempt to normalise S-LVWS. However, if this is insufficient, decompensation occurs and S-LVWS and D-LVWS increase.<xref rid="R1" ref-type="bibr">1</xref><xref rid="R4" ref-type="bibr">4</xref> Therefore, measuring LVWS in these conditions may be a useful way of identifying early cardiac decompensation, which may prompt the need for earlier intervention to prevent permanent myocardial damage. In keeping with this, our group has previously shown that high baseline S-LVWS in AS was associated with worse functional capacity at baseline, suggesting that LVWS may indeed be a useful marker of early decompensation in AS.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> We have also previously demonstrated that TAVR results in a significant reduction in S-LVWS and MC results in a significant reduction in D-LVWS immediately postprocedure.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p><p>In this study, our aims were to determine whether there is any relationship between baseline LVWS and degree of recovery postintervention (both functional and structural) and whether the degree of LVWS reduction at the time of the procedure is predictive of the degree of structural or functional recovery. We assessed LVWS immediately before and after valve intervention using invasively acquired LV pressures combined with measures of LV volumes and wall thickness from cardiac MR imaging (CMR). Cardiac remodelling was assessed on CMR and transthoracic echocardiogram (TTE). Functional status was assessed using a 6&#8201;min walk test (6MWT) preprocedure and 6 months postprocedure.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>Our study was a single-centre prospective study. All research was performed at the Alfred hospital, Melbourne, Australia, between 2018 and 2023. Patients or the public were not involved in the design, conduct, reporting or dissemination plans of this research.</p><sec id="s2-1"><title>Patient enrolment and study design</title><p>47 patients with severe AS approved to undergo TAVR, and 15 patients with severe MR approved to undergo TEER (MC) by the hospital&#8217;s interdisciplinary structural heart team were recruited. Participants were included if they had either severe AS or severe MR awaiting elective TAVR or TEER, respectively, were aged over 18 years with no contraindications to CMR with gadolinium contrast (such as severe claustrophobia, non-CMR compatible metallic implants, allergy to gadolinium or renal impairment with estimated glomerular filtration rate &lt;30&#8201;mL/min). 40/47 AS patients and 11/15 MC patients completed the 6-month follow-up and were included in the analysis. One TAVR patient died from non-cardiac causes, 6 TAVR patients were reluctant to attend follow-up during the peak of the COVID-19 pandemic and 4 MC patients died during the 6-month follow-up period.</p></sec><sec id="s2-2"><title>Investigations</title><p>The methodology used has previously been described,<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> however, in brief, all participants underwent the following three investigations at baseline and 6 months following their TAVR or MC procedure: a 6MWT, a TTE and a CMR. Measures obtained by TTE included: LV mass, wall thickness and relative wall thickness, LV ejection fraction (EF) and left atrial (LA) biplane volumes. CMRs were performed on a 1.5T MRI scanner (Signa Horizon, 5.7, GE Medical Systems; Milwaukee WI) and images were assessed using CVI42 software (CVI42; Circle Cardiovascular Imaging, Calgary, Canada). The CMR protocol followed has also previously been described.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref> Measurements obtained included LV volumes, mass, EF and LA volumes. Non-contrast short-axis T1 mapping was also performed (using MOLLI) and 0.2 mmol/kg Gadovist contrast was administered to allow calculation of myocardial extracellular volume according to standard guidelines.<xref rid="R6" ref-type="bibr"><sup>6</sup></xref> All TTE and CMR images were analysed by a single investigator.</p></sec><sec id="s2-3"><title>Invasive haemodynamic measurement</title><p>During their procedures, patients had LV systolic pressure and end-diastolic pressure recorded immediately pre and post valve/clip deployment using a 6F pigtail catheter placed into the LV via a sheath in the femoral artery.</p></sec><sec id="s2-4"><title>Wall stress calculations</title><p>LVWS was calculated by inputting invasive measures of LV pressure obtained preprocedure and postprocedure and CMR-derived LV measurements of wall thickness and radius into cylinder-based formulas for wall stress calculation (as described previously).<xref rid="R7" ref-type="bibr"><sup>7</sup></xref> The short-axis CMR stack was used to obtain average wall thickness and radius for seven contiguous slices from base (not including mitral valve) to apex. LVWS was calculated for each of the seven contiguous slices, and average LVWS was calculated by summing the values calculated for each slice and dividing by the total number of slices as previously described.<xref rid="R5" ref-type="bibr"><sup>5</sup></xref></p></sec><sec id="s2-5"><title>Statistical analysis</title><p>All data were analysed using SPSS Statistics software (V.26.0; SPSS L). Categorical data are presented as frequencies. Continuous data are presented as mean&#177;SD or as median and IQR depending on normality (assessed using the Shapiro-Wilk test). A p&lt;0.05 was considered statistically significant. Dependent on normality, Student&#8217;s t-tests or Mann-Whitney U tests were used to compare continuous data. Paired t-tests were used to assess normally distributed paired data and Wilcoxon signed-rank tests were used for non-parametric data. Pearson &#967;<sup>2</sup> test was used for categorical data. Pearson coefficients were used to assess the correlation between normally distributed variables and Spearman correlations were used for non-parametric data. Between-group differences (change from baseline and percent change from baseline) were assessed using independent t-tests or Mann-Whitney U tests dependent on normality. Simple linear regression analyses were performed to assess the association between baseline LVWS (as the independent variable) and structural and functional changes (LV mass, end-diastolic volume (EDV), EF and 6MWT) as dependent variables.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3-1"><title>Baseline differences</title><p><xref rid="T1" ref-type="table">Table 1</xref> demonstrates the baseline characteristics of the two cohorts. There was no significant difference in age or baseline 6MWT between the two cohorts (median 296&#8201;m (IQR 182) in the TAVR cohort vs 314&#8201;m (IQR 198) in the MC cohort, p=0.918). However, the MC cohort was a sicker cohort with significantly higher Society of Thoracic Surgeons morbidity and mortality scores.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><title>Baseline characteristics of TAVR and MC cohorts</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1"/><th valign="bottom" rowspan="1" colspan="1">TAVR (n=40)</th><th valign="bottom" rowspan="1" colspan="1">MitraClip (n=11)</th><th valign="bottom" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at procedure (years)</td><td align="left" valign="top" rowspan="1" colspan="1">80.8&#177;6.6</td><td align="left" valign="top" rowspan="1" colspan="1">76.8&#177;8.3</td><td align="left" valign="top" rowspan="1" colspan="1">0.097</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male sex</td><td align="left" valign="top" rowspan="1" colspan="1">73% (n=29)</td><td align="left" valign="top" rowspan="1" colspan="1">91% (n=10)</td><td align="left" valign="top" rowspan="1" colspan="1">0.202</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="left" valign="top" rowspan="1" colspan="1">28.2&#177;3.9</td><td align="left" valign="top" rowspan="1" colspan="1">24.5&#8201;v 3</td><td align="left" valign="top" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ischaemic heart disease (coronary stenosis &gt;50%)</td><td align="left" valign="top" rowspan="1" colspan="1">50% (n=20)</td><td align="left" valign="top" rowspan="1" colspan="1">46% (n=5)</td><td align="left" valign="top" rowspan="1" colspan="1">0.789</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hypertension</td><td align="left" valign="top" rowspan="1" colspan="1">88% (n=35)</td><td align="left" valign="top" rowspan="1" colspan="1">64% (n=7)</td><td align="left" valign="top" rowspan="1" colspan="1">0.066</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" valign="top" rowspan="1" colspan="1">35% (n=14)</td><td align="left" valign="top" rowspan="1" colspan="1">36% (n=4)</td><td align="left" valign="top" rowspan="1" colspan="1">0.378</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Prior open-heart surgery</td><td align="left" valign="top" rowspan="1" colspan="1">10% (n=4)</td><td align="left" valign="top" rowspan="1" colspan="1">27% (n=3)</td><td align="left" valign="top" rowspan="1" colspan="1">0.719</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Preprocedure 6&#8201;min walk test (6MWT)<break/>(metres)</td><td align="left" valign="top" rowspan="1" colspan="1">Median 296<break/>IQR 182</td><td align="left" valign="top" rowspan="1" colspan="1">Median 314<break/>IQR 198</td><td align="left" valign="top" rowspan="1" colspan="1">0.918</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Society of Thoracic Surgeons (STS) Mortality score</td><td align="left" valign="top" rowspan="1" colspan="1">Median 3<break/>IQR 2.9</td><td align="left" valign="top" rowspan="1" colspan="1">Median 4.5<break/>IQR 5.1</td><td align="left" valign="top" rowspan="1" colspan="1">0.016</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">STS Morbidity score</td><td align="left" valign="top" rowspan="1" colspan="1">Median 13.7<break/>IQR 9.1</td><td align="left" valign="top" rowspan="1" colspan="1">Median 16.9<break/>IQR 11.1</td><td align="left" valign="top" rowspan="1" colspan="1">0.049</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Creatinine (mmol/L)</td><td align="left" valign="top" rowspan="1" colspan="1">Median 88<break/>IQR 47</td><td align="left" valign="top" rowspan="1" colspan="1">Median 111<break/>IQR 51</td><td align="left" valign="top" rowspan="1" colspan="1">0.128</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GFR (mL/min)</td><td align="left" valign="top" rowspan="1" colspan="1">Median 69<break/>IQR 40</td><td align="left" valign="top" rowspan="1" colspan="1">Median 54<break/>IQR 28</td><td align="left" valign="top" rowspan="1" colspan="1">0.336</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aortic valve Vmax (m/s)</td><td align="left" valign="top" rowspan="1" colspan="1">4.3&#177;0.5</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Aortic valve mean pressure gradient (mm Hg)</td><td align="left" valign="top" rowspan="1" colspan="1">Median 42<break/>IQR 15</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mechanism of mitral regurgitation</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">10/11 degenerative mitral regurgitation</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Time in trial (days)</td><td align="left" valign="top" rowspan="1" colspan="1">Median 222 days<break/>IQR 91</td><td align="left" valign="top" rowspan="1" colspan="1">Median 214 days<break/>IQR 95</td><td align="left" valign="top" rowspan="1" colspan="1">0.963</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr"><p>GFR, glomerular filtration rate; 6MWT, 6 min walk test; STS, Society of Thoracic Surgeons.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-2"><title>Changes at follow-up irrespective of baseline LVWS</title><sec id="s3-2-1"><title>Structural and functional changes 6 months post-TAVR or MC</title><p><xref rid="T2" ref-type="table">Table 2</xref> shows within group changes in 6MWT and CMR parameters 6 months postprocedure. Overall, both TAVR and MC resulted in an improvement in functional capacity at 6 months as indicated by a significant increase in 6MWT (median 296&#8201;m pre to 353&#8201;m post, p&lt;0.001 in TAVR and 284&#177;127&#8201;m pre, to 344&#177;127&#8201;m post, p=0.009 in MC).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><title>Within-group differences 6 months postintervention in patients undergoing TAVR and MC</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="1" colspan="1"/><th valign="bottom" rowspan="1" colspan="1">Pre-TAVR<break/>(n=40)</th><th valign="bottom" rowspan="1" colspan="1">Post-TAVR<break/>(n=40)</th><th valign="bottom" rowspan="1" colspan="1">P value<xref rid="T2_FN1" ref-type="table-fn">*</xref></th><th valign="bottom" rowspan="1" colspan="1">Change from baseline<break/>(TAVR)</th><th valign="bottom" rowspan="1" colspan="1">Pre-MC<break/>(n=11)</th><th valign="bottom" rowspan="1" colspan="1">Post-MC<break/>(n=11)</th><th valign="bottom" rowspan="1" colspan="1">P value<xref rid="T2_FN1" ref-type="table-fn">*</xref></th><th valign="bottom" rowspan="1" colspan="1">Change from baseline (MC)</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">6MWT</td><td align="left" valign="top" rowspan="1" colspan="1">Median 296<break/>IQR 201&#8211;383</td><td align="left" valign="top" rowspan="1" colspan="1">Median 353<break/>IQR 238&#8211;410</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">Median 43<break/>IQR 72</td><td align="left" valign="top" rowspan="1" colspan="1">283.6&#177;126.7</td><td align="left" valign="top" rowspan="1" colspan="1">344.4&#177;126.9</td><td align="left" valign="top" rowspan="1" colspan="1">0.009</td><td align="left" valign="top" rowspan="1" colspan="1">Median 45<break/>IQR 91</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LV mass</td><td align="left" valign="top" rowspan="1" colspan="1">155.7&#177;38.7</td><td align="left" valign="top" rowspan="1" colspan="1">132.9&#177;31.4</td><td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td><td align="left" valign="top" rowspan="1" colspan="1">&#8722;22.7&#177;23.9</td><td align="left" valign="top" rowspan="1" colspan="1">141.2&#177;26.2</td><td align="left" valign="top" rowspan="1" colspan="1">121.3&#177;32.1</td><td align="left" valign="top" rowspan="1" colspan="1">0.038</td><td align="left" valign="top" rowspan="1" colspan="1">&#8722;21&#177;29.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LV EDV indexed</td><td align="left" valign="top" rowspan="1" colspan="1">Median 78.1<break/>IQR 68&#8211;91</td><td align="left" valign="top" rowspan="1" colspan="1">Median 70.5<break/>IQR 58&#8211;88</td><td align="left" valign="top" rowspan="1" colspan="1">0.03</td><td align="left" valign="top" rowspan="1" colspan="1">Median &#8722;8.4<break/>IQR 22<break/>95%&#8201;CI: &#8722;15 to &#8211;0.2</td><td align="left" valign="top" rowspan="1" colspan="1">Median 112.9<break/>IQR 108.1&#8211;144.3</td><td align="left" valign="top" rowspan="1" colspan="1">Median 106.8<break/>IQR 82.7&#8211;120.5</td><td align="left" valign="top" rowspan="1" colspan="1">0.033</td><td align="left" valign="top" rowspan="1" colspan="1">Median &#8722;16.4,<break/>IQR 31<break/>95%&#8201;CI: &#8722;35 to &#8211;3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Stroke volume (mL)</td><td align="left" valign="top" rowspan="1" colspan="1">81&#177;22.4</td><td align="left" valign="top" rowspan="1" colspan="1">76.9&#177;22.9</td><td align="left" valign="top" rowspan="1" colspan="1">0.351</td><td align="left" valign="top" rowspan="1" colspan="1">Median &#8722;2.7<break/>IQR 19</td><td align="left" valign="top" rowspan="1" colspan="1">103.7&#177;30.6</td><td align="left" valign="top" rowspan="1" colspan="1">80.4&#177;19.6</td><td align="left" valign="top" rowspan="1" colspan="1">0.01</td><td align="left" valign="top" rowspan="1" colspan="1">Median &#8722;23.5<break/>IQR 35</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EF</td><td align="left" valign="top" rowspan="1" colspan="1">Median 59<break/>IQR 48&#8211;64</td><td align="left" valign="top" rowspan="1" colspan="1">Median 59<break/>IQR 48&#8211;66</td><td align="left" valign="top" rowspan="1" colspan="1">0.791</td><td align="left" valign="top" rowspan="1" colspan="1">&#8722;0.2&#177;8.9</td><td align="left" valign="top" rowspan="1" colspan="1">Median<break/>51<break/>IQR 39.5&#8211;59</td><td align="left" valign="top" rowspan="1" colspan="1">Median<break/>47<break/>IQR 40&#8211;53</td><td align="left" valign="top" rowspan="1" colspan="1">0.286</td><td align="left" valign="top" rowspan="1" colspan="1">&#8722;3.9&#177;14</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cardiac outptu (L/min)</td><td align="left" valign="top" rowspan="1" colspan="1">5.3&#177;1.5</td><td align="left" valign="top" rowspan="1" colspan="1">5.5&#177;1.5</td><td align="left" valign="top" rowspan="1" colspan="1">0.493</td><td align="left" valign="top" rowspan="1" colspan="1">Median<break/>0.4<break/>IQR 1.9</td><td align="left" valign="top" rowspan="1" colspan="1">7.9&#177;2.4</td><td align="left" valign="top" rowspan="1" colspan="1">5.7&#177;1.7</td><td align="left" valign="top" rowspan="1" colspan="1">0.001</td><td align="left" valign="top" rowspan="1" colspan="1">Median &#8722;1.9<break/>IQR 1.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Native T1 time</td><td align="left" valign="top" rowspan="1" colspan="1">Median 1045<break/>IQR 999&#8211;1099</td><td align="left" valign="top" rowspan="1" colspan="1">Median 1047<break/>IQR 1011&#8211;1107</td><td align="left" valign="top" rowspan="1" colspan="1">0.757</td><td align="left" valign="top" rowspan="1" colspan="1">Median 9.5<break/>IQR 94</td><td align="left" valign="top" rowspan="1" colspan="1">Median 1070<break/>IQR 1052&#8211;1228</td><td align="left" valign="top" rowspan="1" colspan="1">Median<break/>1012<break/>IQR 996&#8211;1074</td><td align="left" valign="top" rowspan="1" colspan="1">0.037</td><td align="left" valign="top" rowspan="1" colspan="1">Median &#8722;100.5<break/>IQR 202</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ECV</td><td align="left" valign="top" rowspan="1" colspan="1">Median 0.277<break/>IQR 0.22&#8211;0.32</td><td align="left" valign="top" rowspan="1" colspan="1">Median 0.269<break/>IQR 0.24&#8211;0.34</td><td align="left" valign="top" rowspan="1" colspan="1">0.627</td><td align="left" valign="top" rowspan="1" colspan="1">Median 0<break/>OQR 0.1</td><td align="left" valign="top" rowspan="1" colspan="1">Median 0.33<break/>IQR 0.28&#8211;0.425</td><td align="left" valign="top" rowspan="1" colspan="1">Median<break/>0.25<break/>IQR 0.22&#8211;0.42</td><td align="left" valign="top" rowspan="1" colspan="1">0.249</td><td align="left" valign="top" rowspan="1" colspan="1">Median &#8722;0.1<break/>IQR 0.18</td></tr></tbody></table><table-wrap-foot><fn id="T2_FN1" fn-type="other"><label>*</label><p>P value for within group differences.</p></fn><fn fn-type="abbr"><p>ECV, extracellular volume; EDV, end-diastolic volumes; EF, ejection fraction; LV, left ventricular; MC, Mitraclip; 6MWT, 6 min walk test; TAVR, transcatheter aortic valve replacement.</p></fn></table-wrap-foot></table-wrap><p>Both procedures resulted in beneficial remodelling with significant reductions in LV mass (156&#177;39&#8201;pre, 133&#177;31&#8201;gm post, p&lt;0.001 in TAVR and 141&#177;26&#8201;pre vs 121&#177;32&#8201;gm post in MC, p=0.038).</p><p>There were also significant improvements in LV volumes in both cohorts (median 78&#8201;mL/m2 pre to 71&#8201;mL/m2 post in TAVR, p=0.03, median 112&#8201;mL/m2 pre to 107&#8201;mL/m2 post, p=0.033 in MC).</p><p>The MC cohort had a significant reduction in stroke volume and cardiac output postprocedure, whereas the same was not seen with TAVR (between-group differences, p=0.028&#8201;and p&lt;0.001, respectively, in the MC cohort). In both cohorts, there was no significant change in EF postprocedure.</p><p>The MC cohort demonstrated an improvement in diffuse fibrosis (as measured by native T1 on CMR&#8212;T1 time median 1070 IQR 1052&#8211;1228 pre, median 1012, IQR 996&#8211;1074 post, p=0.037).</p></sec></sec><sec id="s3-3"><title>Remodelling at 6 months based on baseline wall stress</title><sec id="s3-3-1"><title>MC cohort</title><p>When the MC cohort was dichotomised into low and high baseline LVWS groups, those with lower baseline D-LVWS showed significant beneficial LV remodelling, with reductions in LV mass and volumes at 6 months (LV mass 137&#177;34&#8201;g pre, 102&#177;28&#8201;g post, p=0.022; LV volumes 217&#177;50&#8201;mL pre, 166&#177;37&#8201;mL post, p=0.032). Significant reductions were not seen in those with high baseline D-LVWS (p values 0.763 and 0.339, respectively).</p><p>Those with higher baseline D-LVWS demonstrated significant reductions in EF post (median EF 53% preprocedure, 47% post, p=0.043) that was not seen in the lower baseline LVWS group (see <xref rid="T3" ref-type="table">table 3</xref>).</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><title>MitraClip: CMR changes at 6 months follow-up based on baseline LVWS</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="bottom" rowspan="2" colspan="1"/><th colspan="3" valign="bottom" rowspan="1">High baseline average D-LVWS<break/>N=5</th><th colspan="3" valign="bottom" rowspan="1">Low baseline average D-LVWS<break/>N=6</th></tr><tr><th valign="top" rowspan="1" colspan="1">Pre-MitraClip</th><th valign="top" rowspan="1" colspan="1">Post-MitraClip</th><th valign="top" rowspan="1" colspan="1">P value</th><th valign="top" rowspan="1" colspan="1">Pre-Mitraclip</th><th valign="top" rowspan="1" colspan="1">Post-MitraClip</th><th valign="top" rowspan="1" colspan="1">P value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">LV mass</td><td valign="top" align="left" rowspan="1" colspan="1">146.5&#177;14.1</td><td valign="top" align="left" rowspan="1" colspan="1">144.6&#177;19.3</td><td valign="top" align="left" rowspan="1" colspan="1">0.763</td><td valign="top" align="left" rowspan="1" colspan="1">136.9&#177;34.1</td><td valign="top" align="left" rowspan="1" colspan="1">101.8&#177;27.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.029</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LV EDV</td><td valign="top" align="left" rowspan="1" colspan="1">244.2&#177;49.5</td><td valign="top" align="left" rowspan="1" colspan="1">233.2&#177;65.6</td><td valign="top" align="left" rowspan="1" colspan="1">0.339</td><td valign="top" align="left" rowspan="1" colspan="1">217.1&#177;50.2</td><td valign="top" align="left" rowspan="1" colspan="1">165.5&#177;37.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.032</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">EF</td><td valign="top" align="left" rowspan="1" colspan="1">Median 53<break/>IQR 42&#8211;60</td><td valign="top" align="left" rowspan="1" colspan="1">Median 47<break/>IQR 30.5&#8211;51</td><td valign="top" align="left" rowspan="1" colspan="1">0.043</td><td valign="top" align="left" rowspan="1" colspan="1">Median 43.6<break/>IQR 36.1&#8211;58</td><td valign="top" align="left" rowspan="1" colspan="1">Median<break/>47.5 IQR 43.4, 59.5</td><td valign="top" align="left" rowspan="1" colspan="1">0.753</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cardiac output (L/min)</td><td valign="top" align="left" rowspan="1" colspan="1">8.9&#177;2.1</td><td valign="top" align="left" rowspan="1" colspan="1">6.4&#177;2.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.002</td><td valign="top" align="left" rowspan="1" colspan="1">7&#177;2.5</td><td valign="top" align="left" rowspan="1" colspan="1">5.1&#177;1.1</td><td valign="top" align="left" rowspan="1" colspan="1">0.064</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td colspan="3" valign="top" align="left" rowspan="1">High baseline average S-LVWS<break/>N=6</td><td colspan="3" valign="top" align="left" rowspan="1">Low baseline average S-LVWS<break/>N=5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stroke Volume (mL)</td><td valign="top" align="left" rowspan="1" colspan="1">108.3&#177;30.3</td><td valign="top" align="left" rowspan="1" colspan="1">81.3&#177;18.8</td><td valign="top" align="left" rowspan="1" colspan="1">0.035</td><td valign="top" align="left" rowspan="1" colspan="1">96.8&#177;44.9</td><td valign="top" align="left" rowspan="1" colspan="1">79&#177;23.7</td><td valign="top" align="left" rowspan="1" colspan="1">0.237</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cardiac Output (L/min)</td><td valign="top" align="left" rowspan="1" colspan="1">8&#177;1.6</td><td valign="top" align="left" rowspan="1" colspan="1">5.6&#177;1.2</td><td valign="top" align="left" rowspan="1" colspan="1">0.012</td><td valign="top" align="left" rowspan="1" colspan="1">7.6&#177;3.4</td><td valign="top" align="left" rowspan="1" colspan="1">5.5&#177;1.5</td><td valign="top" align="left" rowspan="1" colspan="1">0.078</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Left atrial bilplane volume (mL)</td><td valign="top" align="left" rowspan="1" colspan="1">149&#177;45</td><td valign="top" align="left" rowspan="1" colspan="1">138.6&#177;51</td><td valign="top" align="left" rowspan="1" colspan="1">0.49</td><td valign="top" align="left" rowspan="1" colspan="1">Median 203<break/>IQR 165&#8211;223</td><td valign="top" align="left" rowspan="1" colspan="1">Median<break/>151<break/>IQR 133&#8211;195</td><td valign="top" align="left" rowspan="1" colspan="1">0.043</td></tr></tbody></table><table-wrap-foot><fn fn-type="abbr"><p>CMR, cardiac MR; D-LVWS, diastolic LVWS; EDV, end-diastolic volume; EF, ejection fraction; LV, left ventricular; LVWS, left ventricular wall stress; S-LVWS, systolic LVWS.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3-3-2"><title>Linear regression: MC cohort</title><p>Simple linear regression analysis showed that elevated baseline D-LVWS was a predictor of increased LV EDV and reduced EF at follow-up in the MC cohort (R<sup>2</sup>=0.499, F (1,9)=8.952, B=7.857, 95%&#8201;CI: (1.9 to 13.8), p=0.015 for EDV, and R<sup>2</sup> 0.47, F(1,9)=7.945, B=&#8722;1.4, 95%&#8201;CI: (&#8722;2.5 to &#8211;0.3), p=0.02 for EF) (see <xref rid="F1" ref-type="fig">figure 1</xref>).</p><fig position="float" id="F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><title>Scatterplots showing the relationship between baseline LVWS and LV remodelling post-TAVR and MitraClip. Scatterplots demonstrating results of linear regression. Linear regression analysis demonstrated that baseline diastolic LVWS was a predictor of larger LV volumes (<bold>A</bold>) and lower EF (<bold>B</bold>) 6 months post-MitraClip for severe mitral regurgitation. Baseline systolic LVWS was a predictor of larger LV EDV (<bold>C</bold>) and lower EF (<bold>D</bold>), 6 months post-TAVR for severe aortic stenosis (p values all &lt;0.05). EDV, end-diastolic volumes; EF, ejection fraction; LV, left ventricular; LVWS, left ventricular wall stress; TAVR, transcatheter aortic valve replacement.</title></caption><graphic position="float" orientation="portrait" xlink:href="openhrt-12-2-g001.jpg"/></fig></sec></sec><sec id="s3-4"><title>TAVR cohort</title><p>In the TAVR cohort, change in LV mass, LV volume or EF did not vary significantly between the low or high baseline diastolic wall stress groups (p values all non-significant, data not shown).</p><sec id="s3-4-1"><title>Linear regression: TAVR cohort</title><p>Linear regression analysis demonstrated that baseline S-LVWS in AS was a predictor of lower EF and larger LV EDV at follow-up (R<sup>2</sup>=0.31, F(1,38)=16.96, B=&#8722;0.702, 95%&#8201;CI: &#8722;1.05 to &#8211;0.36), p&lt;0.001 for EF, R2=0.11, F(1,38)=4.5, B=1.53, 95%&#8201;CI: (0.07, 3), p=0.04 for EDV) (see <xref rid="F1" ref-type="fig">figure 1</xref>).</p></sec></sec><sec id="s3-5"><title>6 min walk test</title><p>In both cohorts, the level of baseline S-LVWS or D-LVWS did not affect functional outcomes (6MWT) and baseline LVWS was not a predictor of 6MWT at follow-up on linear regression analysis (data not shown).</p></sec><sec id="s3-6"><title>Remodelling at 6 months based on degree of LVWS reduction</title><sec id="s3-6-1"><title>MC cohort</title><p>In the MC cohort, those that had a greater degree of reduction in diastolic wall stress at the time of the procedure showed significant improvements in walk times and native T1 times, but a significant reduction was not seen in those with lower reductions in diastolic wall stress postprocedure (6MWT 316.2&#177;71&#8201;pre vs 387&#177;62.5&#8201;post, p=0.032 in the high D-LVWS reduction group vs p=0.144 in the low D-LVWS reduction group; native T1 time median 1070&#8201;ms pre (IQR 1033, 1581) vs median 1006&#8201;ms post, (IQR 956, 1043) p=0.043 in the high D-LVWS reduction group, (vs p=0.663 in the low D-LVWS reduction group).</p></sec><sec id="s3-6-2"><title>TAVR cohort</title><p>The degree of S-LVWS reduction at the time of TAVR did not affect the degree of cardiac remodelling seen 6 months postprocedure (data not shown).</p></sec><sec id="s3-6-3"><title>Linear regression</title><p>The degree of LVWS reduction at the time of the procedure (both systolic and diastolic) was not a predictor of EF, EDV, LV mass or 6MWT at follow-up in either cohort (data not shown).</p></sec></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>In this study, we investigated the relationship between baseline LVWS and degree of functional and structural improvements 6 months post-TAVR and MC to determine if LWVS can be used to predict the degree of recovery postintervention. This is the first paper, as far as we are aware, assessing the relationship between LVWS and LV recovery poststructural interventions. We found that overall, both procedures resulted in beneficial structural improvements with reductions in LV mass and volumes and significant improvements in functional capacity, in keeping with other literature.<xref rid="R8" ref-type="bibr">8</xref><xref rid="R12" ref-type="bibr">12</xref></p><sec id="s4-1"><title>LVWS and relationship with outcomes</title><sec id="s4-1-1"><title>Transcatheter aortic valve replacement</title><p>In those undergoing TAVR, we found that baseline S-LVWS was a predictor of poorer EF and larger LV EDV at 6 months follow-up. This suggests that there is a threshold of S-LVWS, above which permanent myocardial damage occurs, resulting in less beneficial cardiac remodelling postintervention for severe AS.</p></sec><sec id="s4-1-2"><title>MitraClip</title><p>In those undergoing MC for severe MR, we found that baseline D-LVWS was a predictor of poorer EF and larger LV EDV at 6 months follow-up. Again, this suggests, that in patients with severe MR, there is a threshold of D-LVWS, above which permanent myocardial damage occurs, resulting in less beneficial structural changes postintervention. In keeping with this, MC patients with lower degrees of baseline LVWS showed significant improvements in cardiac remodelling with respect to LV mass, volumes and LA size, whereas there was no significant change seen in those with higher levels of baseline LVWS. These findings suggest that intervening below a certain threshold of D-LVWS may help prevent adverse structural outcomes.</p></sec></sec><sec id="s4-2"><title>LVWS to guide timing of intervention</title><sec id="s4-2-1"><title>Current guidelines for intervention</title><p>With the increasing uptake of structural interventions and improved procedural outcomes over the years, there is great interest in finding markers to help guide optimal timing of intervention. Our previous understanding of the natural history of AS was based on a seminal observational study from the 1960s which suggested there was a long latent asymptomatic period with a sharp increase in mortality occurring once symptoms developed.<xref rid="R13" ref-type="bibr"><sup>13</sup></xref> The emergence of symptoms in severe AS is therefore an indication for intervention, as is the presence of symptoms in severe MR.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref></p><p>However, we now have a better understanding of the natural history of both AS and MR and appreciate that myocardial damage usually occurs well before the onset of symptoms.<xref rid="R15" ref-type="bibr">15</xref><xref rid="R19" ref-type="bibr">19</xref> Currently, valve intervention is warranted in the context of severe and symptomatic disease, or, in the absence of symptoms, when there is a fall in EF<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> (which is used as a crude marker of cardiac decompensation). However, in the context of altered loading conditions (such as in AS and MR), EF is not a reliable indicator of contractility or cardiac decompensation. Furthermore, changes in EF often occur late, once changes in LVWS with resulting myocardial fibrosis and myocardial damage have already occurred.</p><p>This is shifting the focus towards finding markers to guide earlier intervention and prevent permanent myocardial damage. Markers such as abnormal strain, elevated Brain Natriuretic Peptide (BNP), high-sensitivity troponin and cardiac fibrosis on CMR have all been investigated as potential markers to help guide earlier intervention.<xref rid="R14" ref-type="bibr">1419</xref><xref rid="R21" ref-type="bibr">21</xref> All of these markers have been shown to be associated with worse outcomes in both AS<xref rid="R20" ref-type="bibr">2022</xref><xref rid="R25" ref-type="bibr">25</xref> and MR.<xref rid="R18" ref-type="bibr">1826</xref><xref rid="R28" ref-type="bibr">28</xref> Currently, however, only the use of BNP in AS has made its way into the most recent American Heart Association/American College of Cardiology (AHA/ACC) valve disease guidelines, carrying a level 2aB recommendation to guide intervention in asymptomatic severe disease.<xref rid="R14" ref-type="bibr"><sup>14</sup></xref> This demonstrates the need for further research to find more robust evidence for the use of such markers to guide earlier intervention.</p><p>Based on our study, LVWS may prove to be a useful tool in the diagnostic work-up of AS and MR, particularly in patients who might not meet classic level 1 evidence for valve intervention (eg, asymptomatic patients with normal LV dimensions and EF). Elevated S-LVWS may be viewed as a marker of decompensation in AS, and elevated D-LVWS may be viewed as a marker of decompensated MR, prompting earlier intervention to minimise the chance of less beneficial remodelling postprocedure. However, larger trials are warranted to confirm our findings and to define a threshold of LVWS that might represent decompensation.</p></sec></sec><sec id="s4-3"><title>Ease of use of LVWS as a marker</title><p>LVWS in this study was calculated invasively using pressures acquired at the time of intervention which should be feasible in clinical practice as most patients with severe valvular disease being worked up for structural interventions undergo invasive angiography as part of their diagnostic work-up, providing an opportunity for LVWS calculation. Integrating LV pressures with imaging data would allow for calculation of baseline LVWS which may be used as an additional tool when deciding on the need for intervention.</p></sec><sec id="s4-4"><title>Limitations</title><p>The main limitation of this study is the small study numbers. This was a single-centre invasive study that ran during the COVID-19 pandemic. The low numbers in particular affect the MC group when dichotomised into high and low baseline LVWS. For this reason, our findings should be considered hypothesis generating and larger studies are needed to confirm our findings. A further limitation is that LVWS was calculated using pressures obtained during the TAVR or MC procedure. The effect that sedation, anaesthesia, medications or fluids may have had on LV pressures or LVWS was not recorded or assessed.</p></sec></sec><sec sec-type="conclusions" id="s5"><title>Conclusions</title><p>This study demonstrates that high baseline S-LVWS in AS, and high D-LVWS in MR are predictors of less beneficial cardiac remodelling post structural intervention. This suggests that in AS and MR, intervening below a certain LVWS threshold may help improve outcomes with regard to cardiac remodelling postprocedure.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> AT is supported by an NHMRC Leadership Investigator grant and A/Professor DS is supported by National Heart Foundation and NHMRC Research Fellowships.</p></fn><fn fn-type="other"><p><bold>Data availability free text:</bold> N/A.</p></fn><fn fn-type="other"><p><bold>Patient consent for publication:</bold> Not applicable.</p></fn><fn fn-type="other"><p><bold>Ethics approval:</bold> Informed consent was obtained from all participants. The study was approved by the relevant Ethics Committee (Alfred Health Human Research Ethics Committee number 37-15, approved 14/5/2015) and carried out under their guidelines.</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grossman</surname><given-names>W</given-names></name><name name-style="western"><surname>Jones</surname><given-names>D</given-names></name><name name-style="western"><surname>McLaurin</surname><given-names>LP</given-names></name></person-group><article-title>Wall stress and patterns of hypertrophy in the human left ventricle</article-title><source>J Clin Invest</source><year>1975</year><volume>56</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1172/JCI108079</pub-id><pub-id pub-id-type="pmid">124746</pub-id><pub-id pub-id-type="pmcid">PMC436555</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grossman</surname><given-names>W</given-names></name><name name-style="western"><surname>Paulus</surname><given-names>WJ</given-names></name></person-group><article-title>Myocardial stress and hypertrophy: a complex interface between biophysics and cardiac remodeling</article-title><source>J Clin Invest</source><year>2013</year><volume>123</volume><fpage>3701</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1172/JCI69830</pub-id><pub-id pub-id-type="pmid">23999445</pub-id><pub-id pub-id-type="pmcid">PMC3754273</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>SANDLER</surname><given-names>H</given-names></name><name name-style="western"><surname>DODGE</surname><given-names>HT</given-names></name></person-group><article-title>LEFT VENTRICULAR TENSION AND STRESS IN MAN</article-title><source>Circ Res</source><year>1963</year><volume>13</volume><fpage>91</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1161/01.res.13.2.91</pub-id><pub-id pub-id-type="pmid">14047642</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hood</surname><given-names>WP</given-names></name><name name-style="western"><surname>Rackley</surname><given-names>CE</given-names></name><name name-style="western"><surname>Rolett</surname><given-names>EL</given-names></name></person-group><article-title>Wall stress in the normal and hypertrophied human left ventricle</article-title><source>Am J Cardiol</source><year>1968</year><volume>22</volume><fpage>550</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/0002-9149(68)90161-6</pub-id><pub-id pub-id-type="pmid">4235077</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papapostolou</surname><given-names>S</given-names></name><name name-style="western"><surname>Kearns</surname><given-names>J</given-names></name><name name-style="western"><surname>Costello</surname><given-names>BT</given-names></name><etal>et al</etal></person-group><article-title>Comparison of Pressure vs Volume Overload Ventricular Wall Stress in Patients With Valvular Heart Disease</article-title><source>J Am Coll Cardiol</source><year>2024</year><volume>84</volume><fpage>635</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2024.04.068</pub-id><pub-id pub-id-type="pmid">39111970</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Messroghli</surname><given-names>DR</given-names></name><name name-style="western"><surname>Moon</surname><given-names>JC</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>VM</given-names></name><etal>et al</etal></person-group><article-title>Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI)</article-title><source><italic toggle="yes">J Cardiovasc Magn Reson</italic></source><year>2017</year><volume>19</volume><elocation-id>75</elocation-id><pub-id pub-id-type="doi">10.1186/s12968-017-0389-8</pub-id><pub-id pub-id-type="pmid">28992817</pub-id><pub-id pub-id-type="pmcid">PMC5633041</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="report"><person-group person-group-type="author"><collab>The Engineering ToolBox</collab></person-group><article-title>Stress in thick-walled cylinders or tubes</article-title><year>2005</year></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papadopoulos</surname><given-names>K</given-names></name><name name-style="western"><surname>Ikonomidis</surname><given-names>I</given-names></name><name name-style="western"><surname>Chrissoheris</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>MitraClip and left ventricular reverse remodelling: a strain imaging study</article-title><source>ESC Heart Fail</source><year>2020</year><volume>7</volume><fpage>1409</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1002/ehf2.12750</pub-id><pub-id pub-id-type="pmid">32432839</pub-id><pub-id pub-id-type="pmcid">PMC7373921</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feghaly</surname><given-names>J</given-names></name><name name-style="western"><surname>Das</surname><given-names>D</given-names></name><name name-style="western"><surname>Oman</surname><given-names>Z</given-names></name><etal>et al</etal></person-group><article-title>Cardiac Structural Remodeling and Hemodynamic Patterns Following Transcatheter Aortic Valve Replacement</article-title><source>Cureus</source><year>2021</year><volume>13</volume><elocation-id>e19224</elocation-id><pub-id pub-id-type="doi">10.7759/cureus.19224</pub-id><pub-id pub-id-type="pmid">34877202</pub-id><pub-id pub-id-type="pmcid">PMC8642138</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saijo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kusunose</surname><given-names>K</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>T</given-names></name><etal>et al</etal></person-group><article-title>Impact of Transcatheter Aortic Valve Replacement on Cardiac Reverse Remodeling and Prognosis in Mixed Aortic Valve Disease</article-title><source>J Am Heart Assoc</source><year>2024</year><volume>13</volume><elocation-id>e033289</elocation-id><pub-id pub-id-type="doi">10.1161/JAHA.123.033289</pub-id><pub-id pub-id-type="pmid">38362873</pub-id><pub-id pub-id-type="pmcid">PMC11010113</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bagur</surname><given-names>R</given-names></name><name name-style="western"><surname>Rod&#233;s-Cabau</surname><given-names>J</given-names></name><name name-style="western"><surname>Dumont</surname><given-names>E</given-names></name><etal>et al</etal></person-group><article-title>Exercise capacity in patients with severe symptomatic aortic stenosis before and six months after transcatheter aortic valve implantation</article-title><source>Am J Cardiol</source><year>2011</year><volume>108</volume><fpage>258</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2011.03.031</pub-id><pub-id pub-id-type="pmid">21545988</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maisano</surname><given-names>F</given-names></name><name name-style="western"><surname>Franzen</surname><given-names>O</given-names></name><name name-style="western"><surname>Baldus</surname><given-names>S</given-names></name><etal>et al</etal></person-group><article-title>Percutaneous mitral valve interventions in the real world: early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>62</volume><fpage>1052</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2013.02.094</pub-id><pub-id pub-id-type="pmid">23747789</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ross</surname><given-names>J</given-names></name><name name-style="western"><surname>Braunwald</surname><given-names>E</given-names></name></person-group><article-title>Aortic stenosis</article-title><source>Circulation</source><year>1968</year><volume>38</volume><fpage>61</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1161/01.cir.38.1s5.v-61</pub-id><pub-id pub-id-type="pmid">4894151</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Otto</surname><given-names>CM</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>RA</given-names></name><name name-style="western"><surname>Bonow</surname><given-names>RO</given-names></name><etal>et al</etal></person-group><article-title>2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines</article-title><source>Circulation</source><year>2021</year><volume>143</volume><fpage>e35</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1161/CIR.0000000000000932</pub-id><pub-id pub-id-type="pmid">33332149</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flett</surname><given-names>AS</given-names></name><name name-style="western"><surname>Hayward</surname><given-names>MP</given-names></name><name name-style="western"><surname>Ashworth</surname><given-names>MT</given-names></name><etal>et al</etal></person-group><article-title>Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>138</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.930636</pub-id><pub-id pub-id-type="pmid">20585010</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delgado</surname><given-names>V</given-names></name><name name-style="western"><surname>Podlesnikar</surname><given-names>T</given-names></name></person-group><article-title>Focal Replacement and Diffuse Fibrosis in Primary Mitral Regurgitation: A New Piece to the Puzzle</article-title><source>JACC Cardiovasc Imaging</source><year>2021</year><volume>14</volume><fpage>1161</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2020.11.005</pub-id><pub-id pub-id-type="pmid">33341411</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>NC</given-names></name><name name-style="western"><surname>Moody</surname><given-names>WE</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Quantification of left ventricular interstitial fibrosis in asymptomatic chronic primary degenerative mitral regurgitation</article-title><source>Circ Cardiovasc Imaging</source><year>2014</year><volume>7</volume><fpage>946</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1161/CIRCIMAGING.114.002397</pub-id><pub-id pub-id-type="pmid">25140067</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitkungvan</surname><given-names>D</given-names></name><name name-style="western"><surname>Yang</surname><given-names>EY</given-names></name><name name-style="western"><surname>El Tallawi</surname><given-names>KC</given-names></name><etal>et al</etal></person-group><article-title>Prognostic Implications of Diffuse Interstitial Fibrosis in Asymptomatic Primary Mitral Regurgitation</article-title><source>Circulation</source><year>2019</year><volume>140</volume><fpage>2122</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.043250</pub-id><pub-id pub-id-type="pmid">31841370</pub-id><pub-id pub-id-type="pmcid">PMC7556709</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarkar</surname><given-names>A</given-names></name><name name-style="western"><surname>Chowdhury</surname><given-names>S</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><etal>et al</etal></person-group><article-title>Biomarkers as Prognostic Markers for Aortic Stenosis: A Review</article-title><source>Am J Cardiol</source><year>2023</year><volume>206</volume><fpage>53</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2023.08.001</pub-id><pub-id pub-id-type="pmid">37683577</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S-P</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JM</given-names></name><etal>et al</etal></person-group><article-title>Assessment of diffuse myocardial fibrosis by using MR imaging in asymptomatic patients with aortic stenosis</article-title><source>Radiology</source><year>2015</year><volume>274</volume><fpage>359</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1148/radiol.14141120</pub-id><pub-id pub-id-type="pmid">25251584</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Neil</surname><given-names>DAH</given-names></name><name name-style="western"><surname>Premchand</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Myocardial fibrosis in asymptomatic and symptomatic chronic severe primary mitral regurgitation and relationship to tissue characterisation and left ventricular function on cardiovascular magnetic resonance</article-title><source><italic toggle="yes">J Cardiovasc Magn Reson</italic></source><year>2020</year><volume>22</volume><elocation-id>86</elocation-id><pub-id pub-id-type="doi">10.1186/s12968-020-00674-4</pub-id><pub-id pub-id-type="pmid">33308240</pub-id><pub-id pub-id-type="pmcid">PMC7734760</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Everett</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Treibel</surname><given-names>TA</given-names></name><name name-style="western"><surname>Fukui</surname><given-names>M</given-names></name><etal>et al</etal></person-group><article-title>Extracellular Myocardial Volume in Patients With Aortic Stenosis</article-title><source>J Am Coll Cardiol</source><year>2020</year><volume>75</volume><fpage>304</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2019.11.032</pub-id><pub-id pub-id-type="pmid">31976869</pub-id><pub-id pub-id-type="pmcid">PMC6985897</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chin</surname><given-names>CWL</given-names></name><name name-style="western"><surname>Shah</surname><given-names>ASV</given-names></name><name name-style="western"><surname>McAllister</surname><given-names>DA</given-names></name><etal>et al</etal></person-group><article-title>High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><fpage>2312</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehu189</pub-id><pub-id pub-id-type="pmid">24829362</pub-id><pub-id pub-id-type="pmcid">PMC4156973</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ye</surname><given-names>Z</given-names></name><name name-style="western"><surname>Enriquez-Sarano</surname><given-names>M</given-names></name><name name-style="western"><surname>Medina-Inojosa</surname><given-names>JR</given-names></name><etal>et al</etal></person-group><article-title>Incremental Prognostic Value of Semiautomated Left Ventricular Strain to BNP in Asymptomatic Aortic Stenosis</article-title><source>JACC Cardiovasc Imaging</source><year>2022</year><volume>15</volume><fpage>947</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2021.11.021</pub-id><pub-id pub-id-type="pmid">35512962</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elbaz-Greener</surname><given-names>G</given-names></name><name name-style="western"><surname>Ghanim</surname><given-names>D</given-names></name><name name-style="western"><surname>Kusniec</surname><given-names>F</given-names></name><etal>et al</etal></person-group><article-title>Pre- and Post-Transcatheter Aortic Valve Replacement Serum Brain Natriuretic Peptide Levels and All-Cause Mortality</article-title><source>Cardiology</source><year>2020</year><volume>145</volume><fpage>813</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1159/000509857</pub-id><pub-id pub-id-type="pmid">33070124</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopes</surname><given-names>BBC</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>DH</given-names></name><name name-style="western"><surname>Shah</surname><given-names>DJ</given-names></name><etal>et al</etal></person-group><article-title>Importance of Myocardial Fibrosis in Functional Mitral Regurgitation: From Outcomes to Decision-Making</article-title><source>JACC Cardiovasc Imaging</source><year>2021</year><volume>14</volume><fpage>867</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.jcmg.2020.10.027</pub-id><pub-id pub-id-type="pmid">33582069</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klaar</surname><given-names>U</given-names></name><name name-style="western"><surname>Gabriel</surname><given-names>H</given-names></name><name name-style="western"><surname>Bergler-Klein</surname><given-names>J</given-names></name><etal>et al</etal></person-group><article-title>Prognostic value of serial B-type natriuretic peptide measurement in asymptomatic organic mitral regurgitation</article-title><source>Eur J Heart Fail</source><year>2011</year><volume>13</volume><fpage>163</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/eurjhf/hfq189</pub-id><pub-id pub-id-type="pmid">21051463</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mentias</surname><given-names>A</given-names></name><name name-style="western"><surname>Naji</surname><given-names>P</given-names></name><name name-style="western"><surname>Gillinov</surname><given-names>AM</given-names></name><etal>et al</etal></person-group><article-title>Strain Echocardiography and Functional Capacity in Asymptomatic Primary Mitral Regurgitation With Preserved Ejection Fraction</article-title><source>J Am Coll Cardiol</source><year>2016</year><volume>68</volume><fpage>1974</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2016.08.030</pub-id><pub-id pub-id-type="pmid">27591831</pub-id></element-citation></ref></ref-list><sec sec-type="data-availability"><title>Data availability statement</title><p>All data relevant to the study are included in the article or uploaded as supplementary information.</p></sec></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>